spacer
home > ict > spring 2020 > search and rescue
PUBLICATIONS
International Clinical Trials

Search and Rescue





ICT: How can companies identify if a clinical trial needs rescue?

Leslie Jones: It’s certainly a very big decision to make and no sponsor will take changing their CRO lightly. However, there naturally comes a point when missed timelines become critical. Continually failing to meet patient enrolment targets is a major red flag, but it’s important to also look at the reasons behind this. Could these problems have been foreseen or are they a result of poor planning on how and where to recruit patients, poor site selection, and/or poor patient involvement/ retention throughout the study?

Another common problem is vendors ‘lowballing’ their initial cost estimates to win the business, which leaves the CRO under resourced once the complexities of the trial become clear. It is not uncommon for CROs to dedicate less management energy and attention in cases where the sponsor is smaller or medium-sized, but, conversely, this may be the client that requires the most active oversight.

However, ultimately, the decision can come down to whether trust has been broken in the relationship between sponsor and CRO. When all members of the team agree it will be best to change the CRO, it is important to act on this decision and select a replacement with a rescue track record and experience.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Leslie Jones is the Executive Director of Clinical Operations US for WuXi Clinical. She has over 25 years of clinical research experience, ranging from working in a Phase I unit to performing GCP site audits and managing clinical and data teams on large-scale Phase II and Phase III trials. She has a great ability to unify internal and external resources and provides focus to the teams to achieve client goals and outcomes. She has been with WuXi Clinical for over a decade and is based in Austin, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Premier Research Deepens Support for Oncology Sponsors By Expanding Oncology Leadership Team

As the number of next-generation oncology therapies in the clinical trial pipeline surges, Premier Research today announced three new oncology leadership team hires to strengthen the company’s expertise in the fast-growing areas of cell and gene therapies and immuno-oncology.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement